The question is far from academic. Acne is one of the most common reasons transgender and gender-diverse individuals seek dermatological care, and its impact on quality of life in this population can be profound. Prior work published in JAMA Dermatology explored the lived experience of acne and acne treatment among transgender patients, documenting how skin disease intersects with gender affirmation, social functioning, and access to care. Other research has found that moderate-to-severe acne in transmasculine persons who have received testosterone is linked with worse mental health symptoms, since masculinizing hormone therapy can itself trigger or worsen acne. For many patients, isotretinoin therefore represents both a potential solution and a source of anxiety, given the drug’s well-publicized associations with depression and, in rare cases, suicidality.

Those associations remain scientifically contested. A 2024 meta-analysis in JAMA Dermatology assessed the risk of suicide and psychiatric disorders among isotretinoin users and found that the overall evidence is nuanced, with some analyses suggesting no clear causal increase in risk while others point to elevated rates of psychiatric outcomes in certain subgroups. The drug’s label has long carried warnings about depression, psychosis, and suicidal ideation, and regulatory agencies in multiple countries have required monitoring protocols. Yet acne itself is associated with depression, anxiety, and social withdrawal, making it difficult to disentangle the effect of the disease from the effect of its treatment. This confounding problem is especially acute in transgender patients, who face elevated baseline rates of mood disorders, discrimination-related stress, and, for some, additional physiological and psychological shifts during hormone therapy.

Kadam and Lipner addressed the question with a retrospective cohort design, drawing on the de-identified TriNetX Research Network, a large federated platform of electronic health record data from healthcare organizations. TriNetX allows researchers to query millions of patient records using standardized diagnostic and medication codes, making it possible to assemble cohorts of isotretinoin-exposed and unexposed transgender patients and to compare the incidence of downstream psychiatric outcomes. The authors defined exposures and outcomes using ICD-10 diagnostic codes and RxNorm medication codes, the standard vocabularies for encoding diagnoses and prescriptions in electronic health records. This code-based approach is the workhorse of modern pharmacoepidemiology, enabling studies at a scale that would be impossible with manual chart review.

Identifying transgender patients in administrative health data, however, is a methodological challenge in its own right. Gender identity is not consistently recorded in electronic health records, and coding practices vary widely across institutions. To address this, the field has developed validated algorithms that combine diagnosis codes, laboratory orders, hormone prescriptions, and procedure codes to flag transgender and gender-diverse individuals. A 2023 study in the Journal of the American Medical Informatics Association validated such an administrative algorithm against self-reported gender identity data, providing a measure of confidence that code-based identification captures the intended population reasonably well. Kadam and Lipner’s study builds on this methodological foundation, applying established identification strategies to ensure that the cohort reflects transgender and gender-diverse patients rather than miscoded individuals.

The clinical context for this work is a rapidly growing body of literature on dermatologic care in transgender health. A 2024 study in JAMA Dermatology examined isotretinoin use specifically in transgender and gender-diverse individuals receiving masculinizing hormone therapy, highlighting how testosterone-induced acne often requires systemic treatment and how clinicians navigate the psychiatric warning landscape when prescribing to patients who may already be vulnerable. That research, along with the qualitative work on lived experience, established that transgender patients frequently report delayed access to effective acne care and heightened concern about medication side effects. What has been missing is large-scale evidence on whether isotretinoin actually increases psychiatric risk in this specific population, rather than extrapolating from studies of predominantly cisgender patient cohorts.

The retrospective cohort approach has distinct strengths and limitations that shape how the findings should be interpreted. On the strength side, TriNetX provides sample sizes and statistical power that no single-center study can match, and the use of standardized codes reduces some forms of measurement error. Retrospective designs also capture real-world prescribing patterns, including patients who might be excluded from clinical trials. On the limitation side, observational data cannot fully eliminate confounding: patients prescribed isotretinoin tend to have more severe acne, and severity itself correlates with psychological distress. Unmeasured variables, such as social support, hormone therapy timing, and access to mental health care, may differ systematically between exposed and unexposed groups. Electronic health record data also capture only patients who present to care, meaning psychiatric events treated outside the recorded health system may go uncounted.

Because the underlying data are drawn from a licensed, de-identified network, the authors note that patient-level information cannot be shared, though aggregate results are reported in the manuscript and its tables, and the code sets defining exposures and outcomes are documented in the paper. The study received no external funding, and the authors report no conflicts of interest related to the work, although Dr. Lipner has separately served as a consultant for pharmaceutical companies. The journal lists the article as a short report, reflecting a focused research question addressed with a targeted analysis rather than an exhaustive examination of every possible psychiatric outcome and subgroup.

Whatever the specific direction and magnitude of the association the study reports, its significance lies in filling a conspicuous evidence gap. Dermatologists prescribing isotretinoin to transgender patients have until now had to rely on risk estimates derived from populations that may not share the same baseline psychiatric profile, hormone exposures, or social stressors. If the study finds no meaningful elevation in psychiatric events among exposed transgender patients, it could reassure clinicians and patients that the drug’s benefits for severe acne outweigh its psychiatric risks in this group, potentially reducing a barrier to care. If it does identify an elevated risk, it would argue for enhanced screening, closer monitoring during treatment, and coordinated care between dermatology and mental health services tailored to transgender patients’ needs.

The study also arrives amid broader calls to include gender-diverse populations in dermatology research and clinical trials. Transgender patients frequently report that treatment guidelines feel designed for other people, and the acne literature is a case in point: hormone-induced acne in masculinizing therapy follows patterns that standard treatment algorithms were never built to address. Evidence generated specifically in transgender cohorts, using validated identification methods and large real-world datasets, is a step toward care that is both evidence-based and equitable. As isotretinoin continues to be dispensed to a growing number of transgender and gender-diverse patients, studies like this one provide the empirical grounding clinicians need to prescribe with confidence, counsel honestly, and monitor appropriately, ensuring that the pursuit of clear skin never comes at an unexamined cost to mental health.

Subject of Research: Psychiatric safety of isotretinoin treatment for acne in transgender and gender-diverse patients

Article Title: Isotretinoin and psychiatric risk in transgender patients: a retrospective cohort study

Article References: Kadam, P., & Lipner, S. R. (2026). Isotretinoin and psychiatric risk in transgender patients: a retrospective cohort study. Archives of Dermatological Research, 318(1), Article 393. https://doi.org/10.1007/s00403-026-04869-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04869-0

Keywords: isotretinoin, transgender health, psychiatric risk, acne, dermatology, retrospective cohort study, TriNetX, electronic health records, gender-diverse patients, hormone therapy, pharmacoepidemiology, mental health